TruScreen Limited, together with its subsidiaries, develops, manufactures, and sells cancer detection devices and systems in New Zealand.
+ 2 more risks
Adequate balance sheet and overvalued.
Share Price & News
How has TruScreen's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: TRU has not had significant price volatility in the past 3 months.
7 Day Return
NZ Medical Equipment
1 Year Return
NZ Medical Equipment
Return vs Industry: TRU underperformed the NZ Medical Equipment industry which returned 51.4% over the past year.
Return vs Market: TRU underperformed the NZ Market which returned 21.1% over the past year.
Price Volatility Vs. Market
How volatile is TruScreen's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StWhat Kind Of Shareholders Own TruScreen Limited (NZSE:TRU)?
3 months ago | Simply Wall StWhy TruScreen Limited's (NZSE:TRU) CEO Pay Matters To You
4 months ago | Simply Wall StDo Directors Own TruScreen Limited (NZSE:TRU) Shares?
Is TruScreen undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate TRU's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate TRU's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: TRU is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.
PE vs Market: TRU is unprofitable, so we can't compare its PE Ratio to the NZ market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate TRU's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: TRU is good value based on its PB Ratio (2x) compared to the XO Medical Equipment industry average (5.5x).
How is TruScreen forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as TruScreen has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine TruScreen's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- TruScreen competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Healthcare industry.
How has TruScreen performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: TRU is currently unprofitable.
Growing Profit Margin: TRU is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: TRU is unprofitable, and losses have increased over the past 5 years at a rate of -26.4% per year.
Accelerating Growth: Unable to compare TRU's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TRU is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (12.8%).
Return on Equity
High ROE: TRU has a negative Return on Equity (-25.72%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
How is TruScreen's financial position?
Financial Position Analysis
Short Term Liabilities: TRU's short term assets (NZ$4.5M) exceed its short term liabilities (NZ$1.4M).
Long Term Liabilities: TRU's short term assets (NZ$4.5M) exceed its long term liabilities (NZ$57.5K).
Debt to Equity History and Analysis
Debt Level: TRU's debt to equity ratio (5.4%) is considered satisfactory.
Reducing Debt: TRU's debt to equity ratio has reduced from 5.8% to 5.4% over the past 5 years.
Inventory Level: TRU has a low level of unsold assets or inventory.
Debt Coverage by Assets: TRU's debt is covered by short term assets (assets are 7.3x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TRU has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: TRU has less than a year of cash runway if free cash flow continues to reduce at historical rates of -12.7% each year
What is TruScreen's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate TRU's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate TRU's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if TRU's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if TRU's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of TRU's dividend in 3 years as they are not forecast to pay a notable one for the NZ market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Tony Ho (61yo)
Mr. Anthony Peng Ho, also known as Tony, B.Comm, CA, FAICD, FCIS, FGIA, serves as the Chairman and Interim Chief Executive Officer at TruScreen Limited. He has been an Executive Director of Newfield Resour ...
|Chairman & Interim CEO||0yrs||NZ$33.56k||0.62% NZ$141.4k|
|CFO & Company Secretary||1.3yrs||no data||0.045% NZ$10.3k|
|General Manager of Operations||1.6yrs||no data||no data|
|Manager of Administration||1.8yrs||no data||no data|
|Head of Cancer Department||0yrs||no data||no data|
|Head of Research & Development and Training Department||0yrs||no data||no data|
|Head of High Service Gynaecology Examination||0yrs||no data||no data|
Experienced Management: TRU's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.
|Chairman & Interim CEO||0yrs||NZ$33.56k||0.62% NZ$141.4k|
|Chairman of Medical Advisory Board||0yrs||no data||no data|
|Independent Director||6.3yrs||NZ$40.00k||0.68% NZ$156.5k|
|Member of Medical Advisory Board||0yrs||no data||no data|
|Non-Executive Director & Member of Medical Advisory Board||2.3yrs||NZ$56.70k||no data|
|Non-Executive Director||2.2yrs||NZ$40.00k||8.79% NZ$2.0m|
|Non-Executive Director||1.5yrs||NZ$25.15k||no data|
|Alternate Director||1.3yrs||no data||0.12% NZ$26.5k|
Experienced Board: TRU's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: TRU insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 18.8%.
TruScreen Limited's company bio, employee growth, exchange listings and data sources
- Name: TruScreen Limited
- Ticker: TRU
- Exchange: NZSE
- Founded: 2013
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: NZ$22.981m
- Shares outstanding: 227.53m
- Website: https://www.truscreen.com
- TruScreen Limited
- Equitable House
- Level 6
- New Zealand
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|TRU||NZSE (New Zealand Stock Exchange)||Yes||Ordinary Shares||NZ||NZD||Nov 2014|
TruScreen Limited, together with its subsidiaries, develops, manufactures, and sells cancer detection devices and systems in New Zealand. The company offers the TruScreen cervical cancer screening system, a medical device for detecting the presence of precancerous and cancerous tissue on the cervix in real time. It also distributes products in China, Russia, Zimbabwe, Mexico, Papua New Guinea, and internationally. TruScreen Limited was incorporated in 2013 and is headquartered in Auckland, New Zealand.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/18 10:48|
|End of Day Share Price||2020/02/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.